Glizamide PM 30 Tablet combines Gliclazide 30mg, Pioglitazone 15mg, and Metformin 500mg in a single oral formulation, providing a potent triple-action therapy for patients with type-2 diabetes mellitus. It is ideal for those who need comprehensive glycemic control with improved insulin sensitivity and pancreatic support.
Gliclazide stimulates insulin secretion, Pioglitazone improves peripheral insulin sensitivity, and Metformin reduces hepatic glucose output. Together, they offer balanced control of fasting and postprandial blood sugar levels, supporting long-term metabolic stability.
This triple-combination tablet is especially beneficial for patients not adequately controlled by dual therapy or monotherapy, offering efficacy, safety, and convenience in a single daily dosage. It is suitable for both outpatient and hospital-based diabetes management programs.
Adding Glizamide PM 30 Tablet to your diabetes and metabolic-care portfolio strengthens your offerings, unlocking opportunities in hospital supply, retail pharmacy distribution, institutional procurement, export channels, and third-party manufacturing. Its broad clinical applicability ensures continuous demand and strong market performance.